참여증명서 발급문의하기사이트맵

ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.

전체 2295건의 자료가 검색되었습니다.

Excel Download

코로나19(COVID19) 임상시험 현황
No. Status Study Title Conditions Interventions Phase Sponsor/Collaborators Funder Type Number Enrolled Sex Age Locations
2232 Completed A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Coronavirus Infection Drug: ArtemiC
Drug: Placebo
Phase 2 MGC Pharmaceuticals d.o.o INDUSTRY 50 All 18 Years Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, Maharashtra, India
Hillel Yaffe Medical Center, Hadera, Haifa, Israel
Nazareth Hospital EMMS, Nazareth, North, Israel
Rambam Health Care Campus, Haifa, Israel
2231 Unknown status A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above SARS-CoV-2 Biological: SARS-CoV-2 mRNA Vaccine
Biological: Placebo
Phase 3 Walvax Biotechnology Co., Ltd., Abogen Biosciences Co. Ltd., Yuxi Walvax Biotechnology Co., Ltd. INDUSTRY 28000 All 18 Years Persahabatan Hospital, Jakarta, Indonesia
Puskesmas Duren Sawit, Jakarta, Indonesia
Puskesmas Kalideres, Jakarta, Indonesia
Puskesmas Kebayoran Lama, Jakarta, Indonesia
Puskesmas Pulogadung, Jakarta, Indonesia
Centro de Investigacion Clinica del Pacifico S.A. de C.V. (CICPA), Acapulco, Mexico
Centro de Investigacion y Avances Medicos Especializados (CIAME), Cancun, Mexico
Centro de Especialidades Medicas Aplicadas, Mexico city, Mexico
Instituto Nacional de Pediatria (INP), Mexico city, Mexico
Oaxaca site management organization (OSMO), Oaxaca, Mexico
Asociacion Mexicana para la investigacion clinica, A.C. (AMIC), Pachuca, Mexico
Oncologico Potosino, San Luis Potosi, Mexico
2230 Unknown status A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE SARS-CoV Infection Biological: Gam-COVID-Vac
Other: placebo
Phase 3 Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, PDC-CRO OTHER 1000 All 18 Years
2229 Completed A Phase III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. SARS CoV 2 Infection Biological: PHH1-V Phase 3 Hipra Scientific, S.L.U, Veristat, Inc., Asphalion, Fundacion FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promocion de la Salud y la Ciencia, Institut d'Investigacio Biomedica de Girona Dr. Josep Trueta INDUSTRY 241 All 18 Years Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital Josep Trueta, Girona, Spain
Hacettepe University Medical Faculty Hospitals, Ankara, Turkey
Ankara University Medical Faculty Hospitals, Ankara, Turkey
Koc University Hospital, Istanbul, Turkey
2228 Completed A Phase III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. SARS CoV 2 Infection Biological: PHH1-V Phase 3 Hipra Scientific, S.L.U, Veristat, Inc., Asphalion, Fundacion FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promocion de la Salud y la Ciencia, Institut d'Investigacio Biomedica de Girona Dr. Josep Trueta INDUSTRY 241 All 18 Years Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital Josep Trueta, Girona, Spain
Hacettepe University Medical Faculty Hospitals, Ankara, Turkey
Ankara University Medical Faculty Hospitals, Ankara, Turkey
Koc University Hospital, Istanbul, Turkey
2227 Unknown status A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Safety and Efficacy Biological: Recombinant new coronavirus vaccine (CHO cell) group
Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group
Phase 3 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. INDUSTRY 28904 All 18 Years Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Biodimed Guayaquil Clinical Research Center, Guayaquil, Guayas, Ecuador
Biodimed Alemania Clinical Research Center, Quito, Pichincha, Ecuador
Biodimed Eloy Alfaro Clinical Research Center, Quito, Pichincha, Ecuador
Fkui-Rscm, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
FK Unpad/RSHS, Bandung, Jawa Barat, Indonesia
Aziz Fatimah Hospital, Faisalabad, Punjab, Pakistan
Avicenna Hospital, Lahore, Punjab, Pakistan
Central Park Teaching Hospital, Lahore, Punjab, Pakistan
National Hospital & Medical Center, Lahore, Punjab, Pakistan
University of Health Sciences, Lahore, Punjab, Pakistan
Al-Shifa Trust Eye Hospital, Rawalpindi, Punjab, Pakistan
Indus Hospital and Health Network, Karachi, Sindh, Pakistan
Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan
Family Hospital No.15, Tashkent, Uzbekistan
GUVD Poliklinika, Tashkent, Uzbekistan
IIV Markaziy Poliklinika, Tashkent, Uzbekistan
Toshkent viloyat IIV Poliklinika, Tashkent, Uzbekistan
2226 Completed A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. SARS-CoV-2 Acute Respiratory Disease Biological: COVID-19 Vaccine 40 ug/dose Phase 3 Hipra Scientific, S.L.U INDUSTRY 2646 All 16 Years Hospital de Niguarda, Milano, Italy
Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain
Hospital de Mollet, Mollet Del Valles, Barcelona, Spain
Hospital Principe de Asturias, Meco, Madrid, Spain
Hospital HM Puerta del Sur, Mostoles, Madrid, Spain
Hospital de Cruces, Barakaldo, Vizcaya, Spain
Hospital HM Delfos, Barcelona, Spain
Hospital Quironsalud Barcelona, Barcelona, Spain
Hospital Vall Hebron, Barcelona, Spain
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital Universitari Dr. Josep Trueta, Girona, Spain
Hospital Gregorio Maranon, Madrid, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital HM Sanchinarro, Madrid, Spain
Hospital Quironsalud Madrid, Madrid, Spain
Hospital HM Monteprincipe, Madrid, Spain
Hospital Regional Universitario de Malaga, Malaga, Spain
Hospital Clinico de Valencia, Valencia, Spain